{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:59:23Z","timestamp":1789963163788,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.vaccine.2004.10.014","type":"journal-article","created":{"date-parts":[[2004,11,13]],"date-time":"2004-11-13T16:59:21Z","timestamp":1100365161000},"page":"1993-1999","source":"Crossref","is-referenced-by-count":54,"title":["Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants"],"prefix":"10.1016","volume":"23","author":[{"given":"Inge","family":"Berthold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luz","family":"Pombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Arciniega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.10.014_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/153871303769201842","article-title":"Biodefense R & D: anticipating future threats, establishing a strategic environment","volume":"1","author":"Smith","year":"2003","journal-title":"Biosecur Bioterror"},{"key":"10.1016\/j.vaccine.2004.10.014_bib2","unstructured":"21 CFR Part 620.20-24, Food and Drug Administration, HHS. Code of Federal Regulations. Subpart C\u2014Anthrax vaccine adsorbed, 4-1-92; 71\u201372"},{"key":"10.1016\/j.vaccine.2004.10.014_bib3","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.282.22.2104","article-title":"Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax","volume":"282","author":"Friedlander","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2004.10.014_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pds.712","article-title":"Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"11","author":"Sever","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2004.10.014_bib5","series-title":"Vaccines","article-title":"Anthrax","author":"Brachman","year":"1999"},{"key":"10.1016\/j.vaccine.2004.10.014_bib6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib7","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib8","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/S0264-410X(03)00109-9","article-title":"Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants","volume":"21","author":"Jendrek","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib9","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines-US perspective","volume":"20","author":"Baylor","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib10","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"229","article-title":"Adjuvant properties of aluminum and calcium compounds","author":"Gupta","year":"1995"},{"key":"10.1016\/j.vaccine.2004.10.014_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1023\/A:1015843210358","article-title":"The importance of surface charge in the optimization of antigen\u2013adjuvant interactions","volume":"8","author":"Callahan","year":"1991","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2004.10.014_bib12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0264-410X(97)00041-8","article-title":"In vivo absorption of aluminum-containing vaccine adjuvants using 26Al","volume":"15","author":"Flarend","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib13","unstructured":"World Health Organization. Production and control of tetanus vaccine, A training curriculum. WHO Geneva, 1994; BLG\/MOD-IV: 17"},{"key":"10.1016\/j.vaccine.2004.10.014_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0076-6879(88)65019-1","article-title":"Production and purification of anthrax toxin","volume":"165","author":"Leppla","year":"1988","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2004.10.014_bib15","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"249","article-title":"Structure and properties of aluminum-containing adjuvants","author":"Hem","year":"1995"},{"key":"10.1016\/j.vaccine.2004.10.014_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-1759(95)00067-K","article-title":"Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model","volume":"183","author":"Reizenstein","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2004.10.014_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2004.10.014_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","article-title":"Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill","volume":"119","author":"Hansen","year":"1989","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2004.10.014_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0264-410X(91)90154-X","article-title":"Predicting the adsorption of proteins by aluminium-containing adjuvants","volume":"9","author":"Seeber","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.287.7.898","article-title":"Bioterrorism preparedness and response: clinicians and public health agencies as essential partners","volume":"287","author":"Gerberding","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2004.10.014_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/IAI.60.2.662-668.1992","article-title":"Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants","volume":"60","author":"Ivins","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.10.014_bib22","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib23","first-page":"150","article-title":"Vaccine efficacy of Bacillus anthracis protective antigen produced in prokaryotic and eukaryotic cells. In: Abstracts of the 94th General Meeting of the American Society for Microbiology. Washington, DC","volume":"E-38","author":"Ivins","year":"1994","journal-title":"Am Soc Microbiol"},{"key":"10.1016\/j.vaccine.2004.10.014_bib24","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/IAI.66.7.3447-3448.1998","article-title":"Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis","volume":"66","author":"Singh","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.10.014_bib25","series-title":"The comprehensive sourcebook of bacterial protein toxins","first-page":"243","article-title":"The bifactorial Bacillus anthracis lethal and oedema toxins","author":"Leppla","year":"1999"},{"key":"10.1016\/j.vaccine.2004.10.014_bib26","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0264-410X(02)00169-X","article-title":"Mechanisms of stimulation of the immune response by aluminum adjuvants","volume":"20","author":"Hogenesch","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.10.014_bib27","unstructured":"21 CFR Part 610.15(a). Food and Drug Administration, HHS. Code of Federal Regulations. Constituent materials 4-1-03:71\u201372"},{"key":"10.1016\/j.vaccine.2004.10.014_bib28","first-page":"71","article-title":"The mode of action of mineral adjuvants","volume":"2","author":"Hennessen","year":"1965","journal-title":"Progr immunobiol stand"},{"key":"10.1016\/j.vaccine.2004.10.014_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00019052-200206000-00018","article-title":"Neurological adverse events associated with vaccination","volume":"15","author":"Piyasirisilp","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.vaccine.2004.10.014_bib30","first-page":"33","article-title":"Anthrax vaccines","volume":"271","author":"Friedlander","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2004.10.014_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1442-200X.2003.01706.x","article-title":"Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine","volume":"45","author":"Kanra","year":"2003","journal-title":"Pediatr Int"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04007790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04007790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T02:05:16Z","timestamp":1585965916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04007790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":31,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0264410X04007790"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.10.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}